Efficacy of using litonit in the combined therapy of infectious-inflammatory kidney lesions in alcoholism

The results of 250 experiments suggest the advisability of using a new antialcoholic metabolite drug, litonit, in combined therapy of infectious-inflammatory kidney disorders occurring in alcoholism. The course of litonit injections does not only increase considerably the content of oxidized and reduced nicotinamide coenzymes, but also normalizes the number of IgA, IgG and IgM. Certain drug-induced functional and immunological shifts are now believed to indicate the increase in the functional renal capacity and enhanced kidney resistance to inflammation.